Cochrane: PARP inhibitors improve survival in HER2-negative, BRCA-mutated breast cancerJune 2, 2021Breast Cancer
Breast cancer: Fertility concerns affect endocrine therapy decisions in young survivorsJune 2, 2021Breast Cancer
Early breast cancer: Trastuzumab emtansine shows survival benefit regardless of NACT usedJune 2, 2021Breast Cancer
Pertuzumab plus high-dose trastuzumab shows activity in HER-2-positive breast cancerJune 2, 2021Breast Cancer
Immediate breast reconstruction delays radiotherapy and increases complicationJune 2, 2021Breast Cancer
Trastuzumab deruxtecan-related lung disease in MBC patients can occur anytime in first yearJune 2, 2021Metastatic Breast CancerBreast Cancer
Optimal Treatment for HR+/HER2- Breast Cancer Patients With Visceral Metastasis June 1, 2021Breast Cancer
Endocrine therapy benefits in premenopausal breast cancer differ by molecular riskMay 26, 2021Breast CancerMetastatic Breast Cancer
